F. Hoffmann-La Roche AG — Sponsor Intelligence | 213 EU Trials

Filter these 213 trials by condition, phase, country and more.

Open in Search →

213 Registered trials

63 Recruiting

146 Completed trials

27 Countries active

150 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I (Other)

Phase III: 85 Phase II/III: 6 Phase II: 44 Phase I/II: 19 Phase III/IV: 1 Phase IV: 4 Phase I: 16 Phase I (Other): 35 Phase I (FiH): 3

Oversight events:

6 serious breaches 23 temporary halts 4 urgent safety measures 11 unexpected events 6 corrective measures across 30 trials

View oversight register →

100%

146 of 146 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Multiple sclerosis 13 Non-small cell lung cancer 11 Obesity 10 Parkinson's disease 5 Non-small cell lung cancer metastatic 5 Overweight 5 Spinal muscular atrophy 5 HER2 positive breast cancer 5 Systemic lupus erythematosus 4 Breast cancer 4 Diffuse large B-cell lymphoma 4 Relapsing-remitting multiple sclerosis 4

Top IMPs

ATEZOLIZUMAB 28 TOCILIZUMAB 15 OCRELIZUMAB 14 TIRAGOLUMAB 13 INAVOLISIB 12 OBINUTUZUMAB 12 BEVACIZUMAB 8 RO7790121 8 RITUXIMAB 7 ALECTINIB 6 CROVALIMAB 6 DIPHENHYDRAMINE HYDROCHLORIDE 6

All trials — page 3

213 total

A Study to Test the Effectiveness and Safety of RO7790121 for induction and maintenance therapy in Patients with Moderately to Severely Acti… Recruiting

2024-513053-69-00 Phase III 16 countries RO7790121
A Study to Understand the Optimization of the Cytokine Release Syndrome Profile for Glofitamab along with Gemcitabine Plus Oxaliplatin in Pa… Recruiting

2024-516791-15-00 Phase II 3 countries
A Study to Evaluate the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients with Spinal Muscular Atrophy who Experience… Recruiting

2023-505161-81-00 Phase IV 2 countries RISDIPLAM
A Study to Assess Distribution, Binding, and Retention of the Monoclonal Antibody Trontinemab in the Brain of Healthy Participants and Patie… Recruiting

2023-509900-14-00 Phase I (Other) 1 country
A Study to Evaluate the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Patients with Spinal Muscul… Recruiting

2023-504508-26-00 Phase IV 2 countries RISDIPLAM
A study to test the biological properties of RO7568282 and whether it is safe in healthy participants and participants with Parkinson’s dise… Recruiting

2024-511110-21-00 Phase I 1 country
A Study to Investigate the Pharmacokinetics (PK) and Safety of Risdiplam in Infants with Spinal Muscular Atrophy Recruiting

2023-505602-42-00 Phase II 6 countries RISDIPLAM
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease (PASADENA) Recruiting

2023-504472-24-00 Phase II 4 countries PRASINEZUMAB
A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N… Recruiting

2022-502980-39-00 Phase III 13 countries ABEMACICLIB; FULVESTRANT; GIREDESTRANT; PALBOCICLIB; RIBOCICLIB
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for SC use) versus plac… Recruiting

2022-502046-28-00 Phase III 7 countries INAVOLISIB; TRASTUZUMAB, PERTUZUMAB
A Study to Compare the Efficacy and Safety of Glofitamab as a Single Agent Versus Investigator’s Choice in Patients with Relapsed/Refractory… Recruiting

2023-503206-37-00 Phase III 4 countries BENDAMUSTINE HYDROCHLORIDE; GLOFITAMAB; LENALIDOMIDE; OBINUTUZUMAB; RITUXIMAB; T…
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons with Severe or Moderate … Recruiting

2023-503906-35-00 Phase I/II 3 countries RO7589655
A study to look at how safe divarasib is when given on its own or in combination with other anti-cancer therapies, and how well these medici… Recruiting

2023-507171-22-00 Phase I/II 6 countries BUDESONIDE; CARBOPLATIN; CISPLATIN; DIVARASIB; PEMBROLIZUMAB; PEMETREXED
A Rollover Study for Patients Previously Enrolled in a Genentech and/or F.Hoffman-La Roche Sponsored Study Recruiting

2023-504263-16-00 Phase III 4 countries ATEZOLIZUMAB; ATEZOLIZUMAB, TIRAGOLUMAB; BEVACIZUMAB; DIVARASIB; ENTRECTINIB; IN…
CO43923 Master Protocol: A Study Evaluating the Safety and Efficacy of Multiple Treatments in Patients with Multiple Myeloma CO43923 Substud… Recruiting

2023-504484-16-00 Phase I/II 4 countries CEVOSTAMAB; IBERDOMIDE; LENALIDOMIDE; TOCILIZUMAB
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination with Che… Recruiting

2023-504264-41-00 Phase I/II 8 countries GLOFITAMAB; OBINUTUZUMAB; RITUXIMAB; TOCILIZUMAB
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis an… Recruiting

2023-505825-15-00 Phase II 4 countries MYCOPHENOLATE MOFETIL; OBINUTUZUMAB
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients with Metastatic Colorectal Cancer (INTRINSIC) Recruiting

2023-505163-37-00 Phase I (Other) 5 countries
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Subcutaneous Glofitamab following Obinutuz… Recruiting

2023-507728-22-00 Phase I (Other) 5 countries
A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of RO7121932 following Intravenous a… Recruiting

2023-509357-31-00 Phase I 7 countries
A Study to Evaluate Efficacy and Safety of Multiple Treatment Combinations in Patients with Metastatic Breast Cancer (MORPHEUS-panBC) Recruiting

2023-503629-20-00 Phase I/II 3 countries ABEMACICLIB; ATEZOLIZUMAB; ATIRMOCICLIB; FULVESTRANT; INAVOLISIB; LETROZOLE; PAC…
A Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent … Recruiting

2023-505625-14-00 Phase I (FiH) 8 countries GLOFITAMAB; OBINUTUZUMAB; TOCILIZUMAB
An Extension Study of trastuzumab emtansine administered as a single agent or in combination with other anti-cancer therapies in patients pr… Recruiting

2023-503479-79-00 Phase II 5 countries ATEZOLIZUMAB; PERTUZUMAB; TRASTUZUMAB EMTANSINE
A Study to Test Inavolisib Treatments in Patients with Early-Stage, PIK3CA-Mutated Breast Cancer Ended

2024-518811-20-00 Phase II 2 countries INAVOLISIB; LETROZOLE; RIBOCICLIB

Showing 49–72 of 213 trials

← All sponsors A–Z